News

Pfizer to Produce Materials For Its COVID-19 Vaccine in Croatia, Says PM

By 20 May 2021
Pfizer to Produce Materials For Its COVID-19 Vaccine in Croatia, Says PM
Pixabay

ZAGREB, 20 May 2021 - Prime Minister Andrej Plenković said on Thursday that Pfizer would produce materials for its COVID-19 vaccine in its pharmaceutical plant in Savski Marof outside Zagreb, which would put Croatia into the group of European countries that manufacture ingredients of certain vaccines.

Plenković informed his cabinet today that he had discussed this matter with Pfizer's chairman and chief executive officer Albert Bourla on Wednesday.

The Savski Marof plant will produce the DNA template for the COVID-19 vaccine. This is an investment of $10 million, and will create jobs for about 30 people.

Plenković recalled that the European Commission had announced that an agreement had been reached with Pfizer on the delivery of 900 million doses of the vaccine against COVID-19 plus an additional 900 million, which means 1.8 billion doses from December 2021 to 2023.

He underscored the fact that in Croatia one in three adults had already received at least one shot of the vaccine against coronavirus infection.

The target is to have at least 50%-55% of the adult population vaccinated by the end of June.

Plenković also informed the cabinet about the Defence Council meeting on the procurement of multipurpose fighter jets. The Council convened on Thursday morning.

He reiterated that providing the armed forces with such aircraft would be "the greatest and the most important procurement for the armed forces."

The procurement will make Croatia an important and credible ally within NATO and will enable the Croatian armed forces to participate in various international missions at a completely different level, he added.

For all you need to know about coronavirus specific to Croatia, including travel, border, and quarantine rules, as well as the locations of vaccination points and testing centers up and down the country, make sure to bookmark our dedicated COVID-19 section and choose your preferred language.

Search